Biggest News Aggregation in the World
๐Ÿ“ฐ Monitoring Recommendations News

Monitoring Recommendations News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Monitoring Recommendations. Real-time updates on events, politics, business and more.

Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19

Press release content from PR Newswire. The AP news staff was not involved in its creation. Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 July 20, 2021 GMT TARRYTOWN, N.Y., July 20, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japanโ€™s Ministry of Health, Labour and Welfare (MHLW) has approved Regeneronโ€™s casirivimab and imdevimab antibody cocktail to tr...
South Africa United States Sarah Cornhill Georged Yancopoulos Regeneron Velocimmune Vesna Tosic
Source: apnews.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)

Published: Apr 12, 2021 TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for app...
United States Myron Cohen Sarah Cornhill Georged Yancopoulos Regeneron Velocimmune Vesna Tosic

Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19

Share this article TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COVโ„ข (casirivimab with imdevimab) 1,200 mg administere...
United Kingdom United States Sarah Cornhill Georged Yancopoulos Regeneron Velocimmune Vesna Tosic

REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa

Columbia University researchers and Regeneron have independently confirmed findings; data included in bioRxiv paper and submitted for peer-reviewed publication Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that researchers in Dr. David Hos Columbia University lab and Regeneron scientists have independently confirmed that REGEN-COV TM (casirivimab and imdevimab antibody cocktail) successfully neutralizes the circulating SARS-CoV-2 variants first identified in the UK (B.1.1.7) a...
South Africa United States United Kingdom Alexandra Bowie Georged Yancopoulos Mark Hudson

Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19

Reduction in overall infections seen within first week, with 100% prevention of symptomatic infections Markedly decreased levels and duration of viral shedding in asymptomatic infections that still occurred in REGEN-COV group Confirmatory Phase 3 results expected early in second quarter Potential application in people who need immediate protection or respond poorly to vaccination REGEN-COV 1,200 mg administered by subcutaneous injection, providing greater convenience and efficiency than inf...
United States Alexandra Bowie David Weinreich Georged Yancopoulos Mark Hudson Regeneron Pharmaceuticals Inc

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized P

TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/ --Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load...
United Kingdom United States David Weinreich Mark Hudson Regeneron Pharmaceuticals Inc Us Department Of Health

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science